Allison M. (2008), ‘Is personalized medicine finally arriving?’, Nature Biotechnology, 26(5): 509–517.
Amin T. and Kesselheim A. S. (2012), ‘Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades’, Health Affairs, 31(10): 2286–2294.
Angell M. (2004), The Truth About the Drug Companies: How They Deceive Us and What to Do About It, New York: Random House.
Bostyn S. J. R. (2016a), ‘Personalised medicine, medical indication patents and patent infringement: Emergency treatment required’, Intellectual Property Quarterly, 2: 151–200.
Bostyn S. J. R. (2016b), ‘Medical treatment methods, medical indication claims and patentability: A quest into the rationale of the exclusion and patentability in the context of the future of personalised medicine’, Intellectual Property Quarterly, 3: 203–230.
Cragg G. M., Grothaus P. G. and Newman D. J. (2014), ‘New horizons for old drugs and drug leads’, Journal of Natural Products, 77(3): 703–723.
Edwards A. M., Isserlin R., Bader G. D., Frye S. V., Willson T. M. and Yu F. H. (2011), ‘Too many roads not taken’, Nature, 470: 163–165.
Elenco E., Underwood L. and Zohar D. (2015), ‘Defining digital medicine’, Nature Biotechnology, 33(5): 460–461.
Gupta H., Kumar S., Roy S. K. and Gaud R. S. (2010), ‘Patent protection strategies’, Journal of Pharmacy and BioAllied Sciences, 2(1): 2–7.
Joyner M. J. and Paneth N. (2015), ‘Seven questions for personalized medicine’, Journal of the American Medical Association, 314(10): 999–1000.
Kapczynski A., Park C. and Sampat B. (2012), ‘Polymorphs and prodrugs and salts (oh my!): An empirical analysis of “secondary” pharmaceutical patents’, PLoS One, 7(12): e49470.
Manners S. (2006), Super Pills: The Prescription Drugs We Love to Take, Vancouver, BC: Raincoast Books.
Moir H. V. J. (2016), ‘Exploring evergreening: Insights from two medicines’, The Australian Economic Review, 49(4): 413–431.
Mullard A. (2012), ‘Drug repurposing programmes get lift off’, Nature Reviews Drug Discovery, 11: 1–2.
Parker S. and Hall B. (2014), ‘Patenting personalized medicines in the UK, Europe and USA’, Pharmaceutical Patent Analyst, 3(2): 163–169.
Peck R.W. (2016), ‘The right dose for every patient’, Nature Reviews Drug Discovery, 15: 145–146.
Schork N. (2015), ‘Personalized medicine: time for one-person trials’, Nature, 520: 609–611.
Sterckx S. and Cockbain J. (2012), Exclusions From Patentability: How Far has the European Patent Office Eroded Boundaries?
Cambridge: Cambridge University Press.
Vernaz N., Haller G., Girardin F., Huttner B., Combescure C., Dayer P., Muscionico D., Salomon J.L., Bonnabry P. (2013), ‘Patented drug extension strategies on healthcare spending: A cost-evaluation analysis’, PLoS Medicine, 10(6): e1001460.
Warren-Jones A. (2016), ‘Regulatory theory: Commercially sustainable markets rely upon satisfying the public interest in obtaining credible goods’, Health Economics, Policy and Law (this issue).